The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1413
Raxibacumab for Anthrax
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved raxibacumab (rax” ee bak’ ue mab; GSK), a fully human monoclonal antibody given by intravenous infusion, for treatment of inhalational anthrax in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate. It was approved under the Animal Efficacy Rule, which allows the FDA to approve drugs that demonstrate efficacy in animals, providing that they would have a reasonable human health benefit and are safe for human use. Raxibacumab is only available from the CDC.

STANDARD TREATMENT — The current management of a known or suspected inhalational exposure to anthrax in adults includes administration of anthrax vaccine adsorbed (AVA), an inactivated cell-free filtrate of an avirulent strain available from the CDC, in a series of 3 0.5-mL SC injections at 2-week intervals, and an appropriate antibiotic, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Raxibacumab for Anthrax
Article code: 1413b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian